Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
3 ASX healthcare shares up 10% to 22% on news
Why Delta Lithium, Liontown, Pact, and Starpharma shares are storming higher
Here's why the Starpharma share price just exploded 50%!
4 ASX healthcare shares charging higher on positive earnings updates
Why IGO, Patriot Battery Metals, Silver Lake, and Starpharma shares are sinking today
Why is this ASX All Ords share sinking 34% on Monday?
Why Legend Mining, Medibank, Starpharma, and Weebit Nano shares are sinking
Why AGL, Retail Food Group, Starpharma, and TPG shares are rising today
Why Bendigo Bank, Block, Megaport, and Starpharma shares are rising today
5 ASX shares trading near 52-week lows that insiders have been buying
3 ASX All Ords shares tumbling into the weekend
Starphama share price lunges 5% on product relaunch
No, Starpharma does not pay dividends at this time.
Starpharma listed on the ASX on 28 September 2000.
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Starpharma Holdings Ltd (ASX: SPL) is an Australian biotechnology company involved in the development of dendrimer products for pharmaceutical, life science, and other applications.
Dendrimers are synthetically manufactured, nanoscale molecules, particularly useful to the pharmaceutical industry for their unique properties as carriers of other molecular structures.
Starpharma describes itself as a world leader in the field. The company is developing programs for drug delivery applications, the treatment of respiratory viruses, and its VivaGel product.
VivaGel can be used for the management and prevention of bacterial vaginosis and as a coating for condoms. The company's VIRALEZE product is an antiviral nasal spray approved for use in many countries, including Europe and the UK.
|01 Dec 2023||$0.14||$0.01||7.41%||383,602||$0.14||$0.14||$0.14|
|30 Nov 2023||$0.14||$0.00||0.00%||1,569,810||$0.14||$0.14||$0.14|
|29 Nov 2023||$0.14||$0.00||0.00%||582,505||$0.14||$0.14||$0.13|
|28 Nov 2023||$0.14||$-0.01||-7.14%||750,847||$0.14||$0.14||$0.13|
|27 Nov 2023||$0.14||$0.00||0.00%||1,345,421||$0.14||$0.14||$0.13|
|24 Nov 2023||$0.14||$0.00||0.00%||73,941||$0.14||$0.14||$0.14|
|23 Nov 2023||$0.14||$0.00||0.00%||90,728||$0.14||$0.14||$0.14|
|22 Nov 2023||$0.14||$0.01||7.41%||134,827||$0.14||$0.14||$0.14|
|21 Nov 2023||$0.14||$-0.01||-7.14%||1,410,988||$0.14||$0.15||$0.14|
|20 Nov 2023||$0.14||$-0.01||-6.67%||2,802,423||$0.15||$0.15||$0.14|
|17 Nov 2023||$0.15||$0.02||14.81%||886,541||$0.14||$0.15||$0.14|
|16 Nov 2023||$0.14||$-0.01||-7.14%||221,107||$0.14||$0.14||$0.14|
|15 Nov 2023||$0.14||$0.00||0.00%||1,612,143||$0.14||$0.15||$0.14|
|14 Nov 2023||$0.14||$0.01||7.41%||693,215||$0.14||$0.15||$0.14|
|13 Nov 2023||$0.14||$-0.01||-7.14%||961,534||$0.14||$0.15||$0.14|
|10 Nov 2023||$0.14||$0.00||0.00%||2,149,344||$0.14||$0.14||$0.14|
|09 Nov 2023||$0.14||$0.00||0.00%||4,643,343||$0.14||$0.16||$0.14|
|08 Nov 2023||$0.14||$0.01||7.41%||392,503||$0.14||$0.14||$0.14|
|07 Nov 2023||$0.14||$-0.01||-7.14%||52,440||$0.14||$0.14||$0.14|
|06 Nov 2023||$0.14||$0.00||0.00%||529,716||$0.14||$0.15||$0.14|
|03 Nov 2023||$0.14||$0.00||0.00%||87,752||$0.15||$0.15||$0.14|
|06 Oct 2023||Jacinth (Jackie) Fairley||Expiry||514,918||$69,513||
As advised by the company. 5,765,207 Performance Rights, lapsed
|05 Dec 2022||Jacinth (Jackie) Fairley||Issued||1,139,651||$621,109||
Issue of securities. 6,280,125 Performance Rights
|Mr Robert Bain Thomas||Non-Executive DirectorNon-Executive Chairman||Dec 2013||
Mr Thomas has a background in financial services and capital markets and is a non-executive director of several Australian listed companies. Formerly Mr Thomas was a Partner of Potter Partners (now UBS) where he was also Head of Research. Mr Thomas is the former Chief Executive Officer (CEO) of County NatWest Securities and then became CEO and then Chairman of Citibank Corporate and Investment Bank in Australia. Mr Thomas has also held the position of Chairman at Australian Wealth Management Ltd (ultimately IOOF Ltd), TAL (Australia's life insurance company) and HeartWare International Inc, the global manufacturer of left ventricular assist heart pumps. Mr Thomas is currently a non-executive director of ASX-listed Biotron Limited and Clarity Pharmaceuticals Limited. He is member of Risk Committee.
|Mr David McIntyre||Non-Executive Director||Mar 2020||
Mr McIntyre has more than 20 years of executive experience including 18 years in the life sciences sector, having held various C-suite level roles at Tessa Therapeutics, Inc., AVITA Therapeutics, Inc., HeartWare International, Inc., and Braeburn, Inc. Mr McIntyre's experience also includes seven years as a Partner at Apple Tree Partners, a life science venture capital and growth equity fund, giving him knowledge of, and contacts in, the US pharma, medical device and biotech markets. During this time, Mr McIntyre served as a non-executive director of several US life science companies. Prior to entering life sciences, Mr McIntyre practiced as a senior attorney at Baker & McKenzie and KPMG specialising in M&A, initial public offerings, and corporate law and held various senior finance roles in both multinational companies and small growth companies. He is Chair of Risk Committee.
|Dr Jacinth (Jackie) Kincaid Fairley||Chief Executive OfficerExecutive Director||Jul 2006||
Dr Fairley has more than 30 years of operational experience in the pharmaceutical and biotechnology industries working in senior management roles with companies including CSL Limited (CSL) and Faulding (now Pfizer). In those roles Dr Fairley had responsibilities which included clinical, regulatory, business development, product development management and general management. At Faulding Dr Fairley was responsible for global product development, regulatory affairs and business development for Faulding's hospital business which operated in more than 60 countries.
|Ms Lynda Cheng||Non-Executive Director||Aug 2021||
Ms Cheng has a background in finance with more than 25 years of experience as a finance executive including more than 15 years at Visy Industries/Pratt Holdings and 10 years in investment banking. She has commercial and international corporate expertise including experience in financial services, manufacturing, export finance, infrastructure, education as well as market entry, growth, and technology. Ms Cheng is currently Director of Corporate Development and Mergers & Acquisitions at Visy Industries / Pratt Holdings and has held various other roles in the group including CFO. Ms Cheng's earlier roles include as a lawyer at Blake Dawson, before moving into investment banking with J.P. Morgan in its Melbourne, Sydney, San Francisco, and New York offices. She is member of Risk Committee.
|Dr Jeff Davies||Non-Executive Director||Apr 2022||
Dr Davies is a former CSL executive with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President & General Manager at CSL for the Asia-Pacific region, and Global Head of Plasma Product Research and Development at CSL-Behring, Switzerland. As Executive Vice President & General Manager at CSL for the Asia-Pacific region, Dr Davies had overall P&L responsibility for the commercial and operational aspects of the business and oversaw the pharmaceutical, plasma, vaccine, and diagnostic businesses in Australia, New Zealand, China, and the broader Asia-Pacific region.
|Dr Russell Basser||Non-Executive Director||Feb 2023||
Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL. Dr Basser has expertise in international drug and vaccine development, having held multiple senior executive roles at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited/CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring/CSL Limited.
|Mr Justin Cahill||Chief Financial OfficerCompany Secretary||Apr 2023||
|Justin Cahil||Chief Financial Officer (CFO) and Company Secretary||
|Justin Cahill||Chief Financial OfficerCompany Secretary||
|Tony Eglezos||VP Business Development||
|J R Paull||VP Development & Regulatory Affairs||
|HSBC Custody Nominees (Australia) Limited||122,237,260||29.78%|
|Jp Morgan Nominees Australia Pty Limited||37,825,457||9.21%|
|Citicorp Nominees Pty Limited||29,722,931||7.24%|
|BNP Paribas Noms Pty Ltd <DRP>||20,532,433||5.00%|
|National Nominees Limited||5,752,680||1.40%|
|Bnp Paribas Nominees Pty Ltd Acf Clearstream||5,064,744||1.23%|
|T & N Argyrides Investments P/L <T & N Argyrides Pension A/C>||5,060,000||1.24%|
|Mr Kingsley Bryan Bartholomew||3,427,025||0.83%|
|Applecross Secretarial Services Pty Ltd <L Gorr Family A/C>||3,361,550||0.82%|
|Ms Jacinth Fairley||3,252,386||0.79%|
|BNP Paribas Nominees Pty Ltd <IN AU Noms Retail Client> DRP>>Agency Lending DRP A/C>||2,814,519||0.69%|
|Mr Peter Murray Jackson DRP>>Agency Lending DRP A/C>||2,620,000||0.64%|
|HSBC Custody Nominees (Australia) Limited A/C 2||2,564,149||0.62%|
|Dollar Coin Investments Pty Ltd <Cousins Discretionary A/C>||2,007,501||0.49%|
|Bell Potter Nominees Ltd||2,000,000||0.49%|
|Evelyn Family Beneficiary Pty Ltd||1,679,537||0.41%|
|Peppertree Custodian Services Pty Ltd <Mulcahy Superannuation>||1,644,450||0.40%|
|Mr Nigel James Baade||1,629,725||0.40%|
|Mr Thomas Harrington Mann||1,567,617||0.38%|
|Mr David Michael Hosey and Mrs Andrea Jane Hosey||1,477,652||0.36%|